Bolt Biotherapeutics vs TuHURA Biosciences
BOLT and HURA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BOLT and HURA compare
TuHURA Biosciences is the larger company, worth 8.2 times as much as Bolt Biotherapeutics ($89.2M against $10.9M).
Bolt Biotherapeutics scores higher on the StockData Score (8 against 0 for TuHURA Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BOLT | HURA |
|---|---|---|
| Size and price | ||
| Market cap | $10.9M | $89.2M |
| Share price | $5.65 | $1.40 |
| Change, 1 year | 23.6% | −31.7% |
| Change, 5 years | −96.9% | −99.9% |
| Beta (5Y) | 0.13 | 1.98 |
| Employees | 23 | 22 |
| StockData Score | ||
| Total score | 8 (better) | 0 |
| Valuation score | 1 (better) | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 5 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 4.3× | – |
| P/B | 1.3× (better) | 4.8× |
| FCF yield | – | −33.5% |
| Fair value | $5.40 | – |
| Margin of safety | −4.6% | – |
| Growth | ||
| Revenue growth (TTM) | −51.3% | – |
| Revenue growth, 5Y average | 102% | – |
| Profitability | ||
| Operating margin | −1098% | – |
| Net margin | −1034% | – |
| Return on equity | −129% (better) | −161% |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Current ratio | 2.05 (better) | 0.18 |
| Altman Z-score | −20.86 | −3.21 (better) |
| Piotroski F-score | 4 (better) | 2 |
| Dividends and buybacks | ||
| Buyback yield | −0.28% (better) | −22.6% |
| Shareholder yield | −0.28% (better) | −22.6% |
| Ownership | ||
| Held by institutions | 31.0% | 14.1% |
| Held by insiders | 12.2% | 4.9% |
| Insider net buying, 12 months | $196K | – |
| Short interest, % of float | 2.8% | 10.2% |
Go deeper
- BOLT stock overview
- BOLT income statement
- BOLT valuation and score
- HURA stock overview
- HURA income statement
- HURA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.